SHANGHAI, May 28, 2023 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor (“TGCT”), will…
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
Popular News
-
Common Uses and Applications for Cantilever Racking Systems
-
How to Use Packaging Tape Effectively for Shipping and Storage
-
Strapping Machines: The Benefits of Automating Your Packaging Process
-
WITH IEG IN CHINA AT CDEPE IN CHENGDU THE ITALIAN CIRCULAR ECONOMY SMES
-
23andMe Publishes Inaugural Environmental, Social and Governance Report
Technology and Entertainment Magazine
Contact us
renewsindustry@gmail.com
+92 318 3083960